董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jung Choi | 女 | Director | 50 | 未披露 | 未持股 | 2020-07-23 |
| Emmett Cunningham | 男 | Director | 59 | 未披露 | 未持股 | 2020-07-23 |
| Ricky Sun | 男 | Director | 47 | 未披露 | 未持股 | 2020-07-23 |
| Douglas Love | 男 | President, Chief Executive Officer and Director | 53 | 338.82万美元 | 未持股 | 2020-07-23 |
| Thomas G. Wiggans | 男 | Director | 68 | 3.60万美元 | 未持股 | 2020-07-23 |
| William D. Young | 男 | Chairman and Director | 75 | 11.51万美元 | 未持股 | 2020-07-23 |
| Muneer A. Satter | 男 | Director | 59 | 未披露 | 未持股 | 2020-07-23 |
| Carol Gallagher | 女 | Director | 56 | 未披露 | 未持股 | 2020-07-23 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Douglas Love | 男 | President, Chief Executive Officer and Director | 53 | 338.82万美元 | 未持股 | 2020-07-23 |
| Sanjay Keswani | 男 | Executive Vice President and Chief Medical Officer | 50 | 162.02万美元 | 未持股 | 2020-07-23 |
| Michael Overdorf | 男 | Executive Vice President and Chief Business Officer | 50 | 未披露 | 未持股 | 2020-07-23 |
| Ted Yednock | 男 | Executive Vice President and Chief Scientific Officer | 62 | 未披露 | 未持股 | 2020-07-23 |
| Jennifer Lew | 女 | Executive Vice President and Chief Financial Officer | 47 | 130.90万美元 | 未持股 | 2020-07-23 |
董事简历
中英对照 | 中文 | 英文- Jung Choi
-
Jung Choi自2020年6月起担任Annexon, Inc.董事会成员。自2015年4月以来，Choi女士一直担任上市生物制药公司全球血液疗法公司的首席业务和战略官，负责企业战略、业务发展、患者宣传和政府事务。2014年4月至2015年3月，Choi女士担任生物技术公司InterMune，Inc.（2014年被Roche Holding AG收购）的企业发展高级副总裁，并于2013年3月至2014年4月担任InterMune的战略和业务发展顾问。在加入InterMune之前，2011年2月至2013年3月，Choi女士领导生物制药公司Chimerix, Inc.的企业和业务发展，担任顾问和企业发展高级副总裁。在此之前，从2001年8月到2010年8月，Choi女士在上市生物制药公司吉利德科学公司担任过多个管理职位，包括领导业务发展、许可和并购活动。在吉利德科学任职期间，Choi女士建立并监督了企业发展小组，并领导了用于治疗乙型肝炎病毒的Hepsera在美国的商业发布。Choi女士获得了学士学位。人类生物学学士和斯坦福大学工商管理硕士学位。
Jung Choi has served as a member of Annexon, Inc.'s board of directors since June 2020. Since April 2015, Ms. Choi has served as Chief Business and Strategy Officer of Global Blood Therapeutics, Inc., a publicly-held biopharmaceutical company, responsible for corporate strategy, business development, patient advocacy, and government affairs. From April 2014 to March 2015, Ms. Choi served as Senior Vice President, Corporate Development for InterMune, Inc., a biotechnology company (acquired by Roche Holding AG in 2014), and served as an adviser on strategy and business development to InterMune from March 2013 to April 2014. Prior to joining InterMune, from February 2011 to March 2013, Ms. Choi led corporate and business development for Chimerix, Inc., a biopharmaceutical company, as a consultant and Senior Vice President, Corporate Development. Prior to that, from August 2001 to August 2010, Ms. Choi held various management positions at Gilead Sciences, Inc., a publicly-held biopharmaceutical company, including leadership of business development, licensing, and mergers and acquisition activities. During her tenure at Gilead Sciences, Ms. Choi built and oversaw the corporate development group, and led the U.S. commercial launch of Hepsera for the treatment of the hepatitis B virus. Ms. Choi received her B.A. in human biology and an M.B.A. from Stanford University. - Jung Choi自2020年6月起担任Annexon, Inc.董事会成员。自2015年4月以来，Choi女士一直担任上市生物制药公司全球血液疗法公司的首席业务和战略官，负责企业战略、业务发展、患者宣传和政府事务。2014年4月至2015年3月，Choi女士担任生物技术公司InterMune，Inc.（2014年被Roche Holding AG收购）的企业发展高级副总裁，并于2013年3月至2014年4月担任InterMune的战略和业务发展顾问。在加入InterMune之前，2011年2月至2013年3月，Choi女士领导生物制药公司Chimerix, Inc.的企业和业务发展，担任顾问和企业发展高级副总裁。在此之前，从2001年8月到2010年8月，Choi女士在上市生物制药公司吉利德科学公司担任过多个管理职位，包括领导业务发展、许可和并购活动。在吉利德科学任职期间，Choi女士建立并监督了企业发展小组，并领导了用于治疗乙型肝炎病毒的Hepsera在美国的商业发布。Choi女士获得了学士学位。人类生物学学士和斯坦福大学工商管理硕士学位。
- Jung Choi has served as a member of Annexon, Inc.'s board of directors since June 2020. Since April 2015, Ms. Choi has served as Chief Business and Strategy Officer of Global Blood Therapeutics, Inc., a publicly-held biopharmaceutical company, responsible for corporate strategy, business development, patient advocacy, and government affairs. From April 2014 to March 2015, Ms. Choi served as Senior Vice President, Corporate Development for InterMune, Inc., a biotechnology company (acquired by Roche Holding AG in 2014), and served as an adviser on strategy and business development to InterMune from March 2013 to April 2014. Prior to joining InterMune, from February 2011 to March 2013, Ms. Choi led corporate and business development for Chimerix, Inc., a biopharmaceutical company, as a consultant and Senior Vice President, Corporate Development. Prior to that, from August 2001 to August 2010, Ms. Choi held various management positions at Gilead Sciences, Inc., a publicly-held biopharmaceutical company, including leadership of business development, licensing, and mergers and acquisition activities. During her tenure at Gilead Sciences, Ms. Choi built and oversaw the corporate development group, and led the U.S. commercial launch of Hepsera for the treatment of the hepatitis B virus. Ms. Choi received her B.A. in human biology and an M.B.A. from Stanford University.
- Emmett Cunningham
-
Emmett Cunningham自2014年12月以来一直担任我们的董事会成员。他是Blackstone Life Sciences的高级董事总经理，于2018年12月加入Clarus Ventures，LLC，作为其收购的一部分。Cunningham博士于2017年1月至2018年11月担任Clarus的董事总经理，领导医疗技术和生物技术领域的投资，包括与制药公司的合作伙伴关系，并于2008年12月至2016年12月担任合伙人。加入Clarus之前，Cunningham从2004年2月到2005年12月担任Eyetech Pharmaceuticals，Inc.（一家私营制药公司）医疗战略高级副总裁，，帮助领导开发Macugen（一种治疗老年性黄斑变性的药物）团队。Cunningham博士是国际公认的传染性和炎症性眼病专家，拥有超过350种出版物。Cunningham博士此前曾担任Restoration Robotics，Inc.（一家上市医疗设备公司）的董事会成员。他还是私营生物技术公司GaleraTherapeutics，Inc.、私营临床阶段制药公司GraybugVision，Inc.、私营临床阶段生物制药公司Lumos Pharma和私营制药公司SFJ Pharmaceutical的董事会成员，并任职于AeriePharmaceuticals，Inc.（一家上市眼科制药公司）的科学顾问委员会。Cunningham博士是与美国眼科学会（American Academy of Ophthalm）和美国白内障和屈光手术学会（American Society of Cataracy and Refractive Surgery）年会联合举办的眼科创新峰会研讨会的创始人和主席。Cunningham博士在德雷克塞尔大学（Drexel University）获得科学学士学位，在约翰霍普金斯大学（Johns Hopkins University）获得人类生物学学士学位、公共卫生硕士学位和硕士学位，并在圣地亚哥加利福尼亚大学（University of California，San Diego）获得神经科学博士学位，以表彰在索尔克研究所（Salk Institute）所做的工作。
Emmett Cunningham has served as a member of our board of directors since December 2014. He is a Senior Managing Director of Blackstone Life Sciences, having joined as part of its acquisition of Clarus Ventures, LLC, in December 2018. Dr. Cunningham was a Managing Director at Clarus from January 2017 to November 2018 where he led investments in the medical technology and biotechnology space including partnerships with pharmaceutical companies, and a Partner from December 2008 to December 2016. Prior to joining Clarus, Dr. Cunningham was the Senior Vice President, Medical Strategy at Eyetech Pharmaceuticals, Inc., a privately-held pharmaceutical company, from February 2004 to December 2005 where he helped lead the team that developed Macugen, a treatment for age-related macular degeneration. Dr. Cunningham is an internationally recognized specialist in infectious and inflammatory eye disease with over 350 publications. Dr. Cunningham previously served as a member of the board of directors of Restoration Robotics, Inc., a publicly-held medical device company. He is also a member of the board of directors of Galera Therapeutics, Inc., a privately-held biotechnology company, Graybug Vision, Inc., a privately-held clinical-stage pharmaceutical company, Lumos Pharma, Inc., a privately-held clinical-stage biopharmaceutical company, and SFJ Pharmaceutical, Inc., a privately-held pharmaceutical company, and serves on the Scientific Advisory Board of Aerie Pharmaceuticals, Inc., a publicly-held ophthalmic pharmaceutical company. Dr. Cunningham is the founder and Chairman of the Ophthalmology Innovation Summit symposium held in conjunction with the annual meetings of the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery. Dr. Cunningham received his B.S. in Science from Drexel University and a B.A. in human biology, M.D. and M.P.H. in public health from Johns Hopkins University and a Ph.D. in neuroscience from the University of California, San Diego for work done at The Salk Institute. - Emmett Cunningham自2014年12月以来一直担任我们的董事会成员。他是Blackstone Life Sciences的高级董事总经理，于2018年12月加入Clarus Ventures，LLC，作为其收购的一部分。Cunningham博士于2017年1月至2018年11月担任Clarus的董事总经理，领导医疗技术和生物技术领域的投资，包括与制药公司的合作伙伴关系，并于2008年12月至2016年12月担任合伙人。加入Clarus之前，Cunningham从2004年2月到2005年12月担任Eyetech Pharmaceuticals，Inc.（一家私营制药公司）医疗战略高级副总裁，，帮助领导开发Macugen（一种治疗老年性黄斑变性的药物）团队。Cunningham博士是国际公认的传染性和炎症性眼病专家，拥有超过350种出版物。Cunningham博士此前曾担任Restoration Robotics，Inc.（一家上市医疗设备公司）的董事会成员。他还是私营生物技术公司GaleraTherapeutics，Inc.、私营临床阶段制药公司GraybugVision，Inc.、私营临床阶段生物制药公司Lumos Pharma和私营制药公司SFJ Pharmaceutical的董事会成员，并任职于AeriePharmaceuticals，Inc.（一家上市眼科制药公司）的科学顾问委员会。Cunningham博士是与美国眼科学会（American Academy of Ophthalm）和美国白内障和屈光手术学会（American Society of Cataracy and Refractive Surgery）年会联合举办的眼科创新峰会研讨会的创始人和主席。Cunningham博士在德雷克塞尔大学（Drexel University）获得科学学士学位，在约翰霍普金斯大学（Johns Hopkins University）获得人类生物学学士学位、公共卫生硕士学位和硕士学位，并在圣地亚哥加利福尼亚大学（University of California，San Diego）获得神经科学博士学位，以表彰在索尔克研究所（Salk Institute）所做的工作。
- Emmett Cunningham has served as a member of our board of directors since December 2014. He is a Senior Managing Director of Blackstone Life Sciences, having joined as part of its acquisition of Clarus Ventures, LLC, in December 2018. Dr. Cunningham was a Managing Director at Clarus from January 2017 to November 2018 where he led investments in the medical technology and biotechnology space including partnerships with pharmaceutical companies, and a Partner from December 2008 to December 2016. Prior to joining Clarus, Dr. Cunningham was the Senior Vice President, Medical Strategy at Eyetech Pharmaceuticals, Inc., a privately-held pharmaceutical company, from February 2004 to December 2005 where he helped lead the team that developed Macugen, a treatment for age-related macular degeneration. Dr. Cunningham is an internationally recognized specialist in infectious and inflammatory eye disease with over 350 publications. Dr. Cunningham previously served as a member of the board of directors of Restoration Robotics, Inc., a publicly-held medical device company. He is also a member of the board of directors of Galera Therapeutics, Inc., a privately-held biotechnology company, Graybug Vision, Inc., a privately-held clinical-stage pharmaceutical company, Lumos Pharma, Inc., a privately-held clinical-stage biopharmaceutical company, and SFJ Pharmaceutical, Inc., a privately-held pharmaceutical company, and serves on the Scientific Advisory Board of Aerie Pharmaceuticals, Inc., a publicly-held ophthalmic pharmaceutical company. Dr. Cunningham is the founder and Chairman of the Ophthalmology Innovation Summit symposium held in conjunction with the annual meetings of the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery. Dr. Cunningham received his B.S. in Science from Drexel University and a B.A. in human biology, M.D. and M.P.H. in public health from Johns Hopkins University and a Ph.D. in neuroscience from the University of California, San Diego for work done at The Salk Institute.
- Ricky Sun
-
Ricky Sun自2018年12月以来一直担任我们的董事会成员。自2016年8月以来，孙博士一直担任贝恩资本生命科学有限公司（Bain Capital Life Sciences，L.P.）的合伙人。在加入贝恩资本之前，他于2013年1月至2016年7月担任上市生物技术公司BiogenInc.的企业发展和战略总监。在加入Biogen之前，孙博士曾担任贝莱德集团公司（BlackRock&；8217；S Alpha Strategies Group）的Vice President、贝莱德（BlackRock&；8217；S Alpha Strategies Group）基础股票部门的成员，以及贝莱德（BlackRock&；8217；S）覆盖医疗保健领域的基础大盘成长股票团队的高级分析师。在此之前，他是Citadel LLC和Alyeska Investment Group的高级梦百合分析师，L.P.于2010年5月至2011年12月在芝加哥工作，并于2006年9月至2007年7月在华尔街担任制药股票研究分析师，在Lehman Brothers HoldingsInc.和摩根士丹利工作。他的职业生涯始于担任Ironwood Pharmaceutical，Inc.的高级科学家（从2002年1月到2009年7月），在那里他曾参与发现和开发用于肠易激综合征的药物Linzess。孙博士担任上市生物制药公司ArcutisBiotherapeutics，Inc.的董事，自2019年12月起，孙博士还担任上市生物制药公司Savara，Inc.的董事。Sun博士在Berea College以优异成绩获得化学学士学位，在New York University Stern School of Business获得工商管理硕士学位，在那里他是Mildred Elperin学者，在Harvard University获得化学和化学生物学博士学位。他也是哈佛医学院（Harvard Medical School）的NIH生物化学&分子药理学博士后。
Ricky Sun has served as a member of our board of directors since December 2018. Since August 2016 Dr. Sun has been a partner at Bain Capital Life Sciences, L.P. Prior to joining Bain Capital, he was a Director of Corporate Development and Strategy at Biogen Inc., a publicly-held biotechnology company, from January 2013 to July 2016. Prior to Biogen, Dr. Sun served as a Vice President at BlackRock, Inc., as a member of the Fundamental Equity division of BlackRock’s Alpha Strategies Group and senior analyst for BlackRock’s Fundamental Large Cap Growth equity team, covering the health care sector. Prior to that, he was a senior healthcare analyst at Citadel LLC and Alyeska Investment Group, L.P. in Chicago from May 2010 to December 2011 and worked as a pharmaceuticals equity research analyst on Wall Street from September 2006 to July 2007 spending time at Lehman Brothers Holdings Inc. and Morgan Stanley. Dr. Sun began his career as a senior scientist at Ironwood Pharmaceutical, Inc. from January 2002 to July 2009 where he was involved in the discovery and development of the drug Linzess for irritable bowel syndrome. Dr. Sun serves as a director of Arcutis Biotherapeutics, Inc., a publicly-held biopharmaceutical company, and, since December 2019 Dr. Sun has also served as a director of Savara, Inc., a publicly-held biopharmaceutical company. Dr. Sun received a B.A. in chemistry, summa cum laude, from Berea College, an M.B.A. from New York University Stern School of Business, where he was a Mildred Elperin Scholar, and a Ph.D. degree in Chemistry and Chemical Biology from Harvard University. He was also an NIH post-doctoral fellow in Biological Chemistry & Molecular Pharmacology at Harvard Medical School. - Ricky Sun自2018年12月以来一直担任我们的董事会成员。自2016年8月以来，孙博士一直担任贝恩资本生命科学有限公司（Bain Capital Life Sciences，L.P.）的合伙人。在加入贝恩资本之前，他于2013年1月至2016年7月担任上市生物技术公司BiogenInc.的企业发展和战略总监。在加入Biogen之前，孙博士曾担任贝莱德集团公司（BlackRock&；8217；S Alpha Strategies Group）的Vice President、贝莱德（BlackRock&；8217；S Alpha Strategies Group）基础股票部门的成员，以及贝莱德（BlackRock&；8217；S）覆盖医疗保健领域的基础大盘成长股票团队的高级分析师。在此之前，他是Citadel LLC和Alyeska Investment Group的高级梦百合分析师，L.P.于2010年5月至2011年12月在芝加哥工作，并于2006年9月至2007年7月在华尔街担任制药股票研究分析师，在Lehman Brothers HoldingsInc.和摩根士丹利工作。他的职业生涯始于担任Ironwood Pharmaceutical，Inc.的高级科学家（从2002年1月到2009年7月），在那里他曾参与发现和开发用于肠易激综合征的药物Linzess。孙博士担任上市生物制药公司ArcutisBiotherapeutics，Inc.的董事，自2019年12月起，孙博士还担任上市生物制药公司Savara，Inc.的董事。Sun博士在Berea College以优异成绩获得化学学士学位，在New York University Stern School of Business获得工商管理硕士学位，在那里他是Mildred Elperin学者，在Harvard University获得化学和化学生物学博士学位。他也是哈佛医学院（Harvard Medical School）的NIH生物化学&分子药理学博士后。
- Ricky Sun has served as a member of our board of directors since December 2018. Since August 2016 Dr. Sun has been a partner at Bain Capital Life Sciences, L.P. Prior to joining Bain Capital, he was a Director of Corporate Development and Strategy at Biogen Inc., a publicly-held biotechnology company, from January 2013 to July 2016. Prior to Biogen, Dr. Sun served as a Vice President at BlackRock, Inc., as a member of the Fundamental Equity division of BlackRock’s Alpha Strategies Group and senior analyst for BlackRock’s Fundamental Large Cap Growth equity team, covering the health care sector. Prior to that, he was a senior healthcare analyst at Citadel LLC and Alyeska Investment Group, L.P. in Chicago from May 2010 to December 2011 and worked as a pharmaceuticals equity research analyst on Wall Street from September 2006 to July 2007 spending time at Lehman Brothers Holdings Inc. and Morgan Stanley. Dr. Sun began his career as a senior scientist at Ironwood Pharmaceutical, Inc. from January 2002 to July 2009 where he was involved in the discovery and development of the drug Linzess for irritable bowel syndrome. Dr. Sun serves as a director of Arcutis Biotherapeutics, Inc., a publicly-held biopharmaceutical company, and, since December 2019 Dr. Sun has also served as a director of Savara, Inc., a publicly-held biopharmaceutical company. Dr. Sun received a B.A. in chemistry, summa cum laude, from Berea College, an M.B.A. from New York University Stern School of Business, where he was a Mildred Elperin Scholar, and a Ph.D. degree in Chemistry and Chemical Biology from Harvard University. He was also an NIH post-doctoral fellow in Biological Chemistry & Molecular Pharmacology at Harvard Medical School.
- Douglas Love
-
Douglas Love自2014年12月以来一直担任我们的总裁兼首席执行官，并担任我们的董事会成员。加入Annexon公司之前，他曾担任Elan Pharmaceuticals公司（生物制药公司）的运营和战略联盟主管（从2008年到2013年4月），在那里他曾领导Tysabri®；多发性硬化症专营权，以及Elan’；s Alzheimer’；s免疫治疗计划（已获得强生公司公司的许可）。从2006年到2008年，他曾担任Elan公司的战略联盟、业务开发和业务集成主管。在加入Elan之前，Love先生曾担任律师事务所Orrick，Herrington&Sutcliffe LLP的合伙人，Amgen，Inc.的公司法律顾问，以及Genentech，Inc.的部门公司法律顾问，在那里他领导了生物肿瘤学梦百合法律集团。Love先生在南加州大学（University of Southern California）获得工商管理学士学位，并在麦乔治法学院（McGeorge School of Law）以优异成绩获得法学博士学位。
Douglas Love has served as our President and Chief Executive Officer and as a member of our board of directors since December 2014. Prior to joining Annexon, from 2008 to April 2013 he served as Head of Operations & Strategic Alliances for Elan Pharmaceuticals, Inc., a biopharmaceutical company, where he led the Tysabri® multiple sclerosis franchise, and Elan’s Alzheimer’s Immunotherapy Program, which was licensed to Johnson & Johnson. From 2006 to 2008 he served as Head of Strategic Alliances, Business Development & Business Integration for Elan. Prior to joining Elan, Mr. Love served as an associate at the law firm Orrick, Herrington & Sutcliffe LLP, Corporate Counsel at Amgen, Inc. and as Section Corporate Counsel at Genentech, Inc., where he led the BioOncology Healthcare Law Group. Mr. Love received a B.S. in business administration from the University of Southern California and a J.D. with great distinction from McGeorge School of Law. - Douglas Love自2014年12月以来一直担任我们的总裁兼首席执行官，并担任我们的董事会成员。加入Annexon公司之前，他曾担任Elan Pharmaceuticals公司（生物制药公司）的运营和战略联盟主管（从2008年到2013年4月），在那里他曾领导Tysabri®；多发性硬化症专营权，以及Elan’；s Alzheimer’；s免疫治疗计划（已获得强生公司公司的许可）。从2006年到2008年，他曾担任Elan公司的战略联盟、业务开发和业务集成主管。在加入Elan之前，Love先生曾担任律师事务所Orrick，Herrington&Sutcliffe LLP的合伙人，Amgen，Inc.的公司法律顾问，以及Genentech，Inc.的部门公司法律顾问，在那里他领导了生物肿瘤学梦百合法律集团。Love先生在南加州大学（University of Southern California）获得工商管理学士学位，并在麦乔治法学院（McGeorge School of Law）以优异成绩获得法学博士学位。
- Douglas Love has served as our President and Chief Executive Officer and as a member of our board of directors since December 2014. Prior to joining Annexon, from 2008 to April 2013 he served as Head of Operations & Strategic Alliances for Elan Pharmaceuticals, Inc., a biopharmaceutical company, where he led the Tysabri® multiple sclerosis franchise, and Elan’s Alzheimer’s Immunotherapy Program, which was licensed to Johnson & Johnson. From 2006 to 2008 he served as Head of Strategic Alliances, Business Development & Business Integration for Elan. Prior to joining Elan, Mr. Love served as an associate at the law firm Orrick, Herrington & Sutcliffe LLP, Corporate Counsel at Amgen, Inc. and as Section Corporate Counsel at Genentech, Inc., where he led the BioOncology Healthcare Law Group. Mr. Love received a B.S. in business administration from the University of Southern California and a J.D. with great distinction from McGeorge School of Law.
- Thomas G. Wiggans
-
Thomas G. Wiggans于2010年8月创立我们公司，自2010年8月以来担任我们的首席执行官和董事会成员，并自2014年4月以来担任我们董事会的主席。他服务于各种行业组织、教育机构以及私人和公共公司的董事会，包括服务于生物制药公司Onyx Pharmaceuticals, Inc.的董事会（从2005年3月到2013年10月他被Amgen Inc.收购），Sangamo Biosciences, Inc.（从2008年6月到2012年6月），Somaxon Pharmaceuticals, Inc.（从2008年6月至2012年5月），是Excaliard Pharmaceuticals, Inc.的董事长（从2010年10月到2011年12月它被Pfizer Inc.收购）。他从2007年10月起担任生物科技公司Peplin, Inc.的董事长，在2008年8月成为其首席执行官，他担任这些职位直到2009年11月Peplin被LEO Pharma A/S收购。之前，他自1994年以来担任生物技术公司Connetics Corporation的首席执行官。自2006年1月以来担任Connetics的董事长，他担任这些职位直到2006年12月Connetics被Stiefel Laboratories, Inc.收购。从1992年到1994年他担任生物技术公司CytoTherapeutics Inc.的总裁兼首席运营官。他从1980年到1992年在Ares-Serono S.A.担任各种管理职位，包括其美国制药业务的总裁和英国制药业务的董事总经理。他在制药公司Eli Lilly and Company开始他的职业生涯。此外，他是非营利性教育机构生物技术研究所（the Biotechnology Institute）的主席，是堪萨斯大学捐赠基金协会（the University of Kansas Endowment Association）的理事会成员。他持有堪萨斯大学（University of Kansas ）的药剂学学士学位，南卫理公会大学（Southern Methodist University）的工商管理硕士学位。
Thomas G. Wiggans has served as a member of our board of directors since February 2017. Mr. Wiggans founded Dermira, Inc., a publicly-held pharmaceutical company, in August 2010 and has served as its Chief Executive Officer since September 2010 and on its board of directors since October 2014. Mr. Wiggans has also served on the boards of various industry organizations, educational institutions and private and public companies, including service on the boards of directors of Onyx Pharmaceuticals from March 2005 until its acquisition by Amgen Inc. in October 2013 Sangamo Biosciences, Inc. from June 2008 until June 2012 Somaxon Pharmaceuticals, Inc. from June 2008 until May 2012 and as Chairman of the board of directors of Excaliard Pharmaceuticals, Inc. from October 2010 until its acquisition by Pfizer, Inc. in December 2011. From October 2007 Mr. Wiggans served as Chairman of the board of directors of Peplin, Inc. and in July 2007 he became its Chief Executive Officer, and he served in these positions until Peplin’s acquisition by LEO Pharma A/S in November 2009. Previously, Mr. Wiggans served as Chief Executive Officer of Connetics Corporation from July 1994 and as Chairman of the board of directors of Connetics from January 2006 and he served in these positions until December 2006 when Connetics was acquired by Stiefel Laboratories, Inc. From 1992 to 1994 Mr. Wiggans served as President and Chief Operating Officer of CytoTherapeutics Inc. From 1980 to 1992 Mr. Wiggans served at Ares-Serono S.A. in various management positions including President of its U.S. pharmaceutical operations and Managing Director of its U.K. pharmaceutical operations. Mr. Wiggans began his career with Eli Lilly & Company. In addition, Mr. Wiggans is a member of the board of directors of the Biotechnology Innovation Organization and is a member of the board of trustees of the University of Kansas Endowment Association. Mr. Wiggans received a B.S. in pharmacy from the University of Kansas and an M.B.A. from Southern Methodist University. - Thomas G. Wiggans于2010年8月创立我们公司，自2010年8月以来担任我们的首席执行官和董事会成员，并自2014年4月以来担任我们董事会的主席。他服务于各种行业组织、教育机构以及私人和公共公司的董事会，包括服务于生物制药公司Onyx Pharmaceuticals, Inc.的董事会（从2005年3月到2013年10月他被Amgen Inc.收购），Sangamo Biosciences, Inc.（从2008年6月到2012年6月），Somaxon Pharmaceuticals, Inc.（从2008年6月至2012年5月），是Excaliard Pharmaceuticals, Inc.的董事长（从2010年10月到2011年12月它被Pfizer Inc.收购）。他从2007年10月起担任生物科技公司Peplin, Inc.的董事长，在2008年8月成为其首席执行官，他担任这些职位直到2009年11月Peplin被LEO Pharma A/S收购。之前，他自1994年以来担任生物技术公司Connetics Corporation的首席执行官。自2006年1月以来担任Connetics的董事长，他担任这些职位直到2006年12月Connetics被Stiefel Laboratories, Inc.收购。从1992年到1994年他担任生物技术公司CytoTherapeutics Inc.的总裁兼首席运营官。他从1980年到1992年在Ares-Serono S.A.担任各种管理职位，包括其美国制药业务的总裁和英国制药业务的董事总经理。他在制药公司Eli Lilly and Company开始他的职业生涯。此外，他是非营利性教育机构生物技术研究所（the Biotechnology Institute）的主席，是堪萨斯大学捐赠基金协会（the University of Kansas Endowment Association）的理事会成员。他持有堪萨斯大学（University of Kansas ）的药剂学学士学位，南卫理公会大学（Southern Methodist University）的工商管理硕士学位。
- Thomas G. Wiggans has served as a member of our board of directors since February 2017. Mr. Wiggans founded Dermira, Inc., a publicly-held pharmaceutical company, in August 2010 and has served as its Chief Executive Officer since September 2010 and on its board of directors since October 2014. Mr. Wiggans has also served on the boards of various industry organizations, educational institutions and private and public companies, including service on the boards of directors of Onyx Pharmaceuticals from March 2005 until its acquisition by Amgen Inc. in October 2013 Sangamo Biosciences, Inc. from June 2008 until June 2012 Somaxon Pharmaceuticals, Inc. from June 2008 until May 2012 and as Chairman of the board of directors of Excaliard Pharmaceuticals, Inc. from October 2010 until its acquisition by Pfizer, Inc. in December 2011. From October 2007 Mr. Wiggans served as Chairman of the board of directors of Peplin, Inc. and in July 2007 he became its Chief Executive Officer, and he served in these positions until Peplin’s acquisition by LEO Pharma A/S in November 2009. Previously, Mr. Wiggans served as Chief Executive Officer of Connetics Corporation from July 1994 and as Chairman of the board of directors of Connetics from January 2006 and he served in these positions until December 2006 when Connetics was acquired by Stiefel Laboratories, Inc. From 1992 to 1994 Mr. Wiggans served as President and Chief Operating Officer of CytoTherapeutics Inc. From 1980 to 1992 Mr. Wiggans served at Ares-Serono S.A. in various management positions including President of its U.S. pharmaceutical operations and Managing Director of its U.K. pharmaceutical operations. Mr. Wiggans began his career with Eli Lilly & Company. In addition, Mr. Wiggans is a member of the board of directors of the Biotechnology Innovation Organization and is a member of the board of trustees of the University of Kansas Endowment Association. Mr. Wiggans received a B.S. in pharmacy from the University of Kansas and an M.B.A. from Southern Methodist University.
- William D. Young
-
William D. Young自2013年10月起担任董事，自2014年4月起担任Theravance Biopharma首席独立董事。在Theravance Biopharma于2014年6月从Innoviva分拆上市之前，Young先生自2001年4月起担任Innoviva的董事。自2018年黑石生命科学收购Claris Ventures以来，他一直担任黑石生命科学的高级顾问。从2010年到2018年，他是Claris Ventures的风险合伙人。Young先生从1999年至2009年担任生物技术公司Monogram Biosciences，Inc.的董事会主席和首席执行官。1980年至1999年，Young先生受雇于基因泰克公司，最近担任首席运营官，负责所有产品开发、制造和商业职能。在加入基因泰克公司之前，Young先生在礼来公司工作了14年。Young先生自2010年起担任生物技术公司NanoString Technologies的董事长，自2017年3月起担任生物技术公司Annexon生物科学公司和Clarus投资组合公司的董事长。此外，Young先生还是上市公司Praxis Precision Medicine和Clarus投资组合公司SFJ Pharmaceuticals的董事会成员。他是Vertex Pharmaceuticals的董事会成员，直到2020年6月，BioMarin，Inc.直到2015年10月，Biogen Idec Inc.直到2014年6月，自1997年起担任董事，自2010年起担任董事会主席。Young先生还是非营利公司Montage Health的受托人。Young先生在印第安纳大学获得工商管理硕士学位，在普渡大学获得化学工程学士学位，并在普渡大学获得荣誉工程学博士学位。
William D. Young has served as a director since October 2013 and has served as Theravance Biopharma, Inc. lead independent director since April 2014. Prior to Theravance Biopharma, Inc. spin-off from Innoviva in June 2014 and since April 2001 Mr. Young served as a director of Innoviva. He has been a Senior Advisor of Blackstone Life Sciences since 2018 when Blackstone Life Sciences acquired Claris Ventures. He was a Venture Partner at Claris Ventures from 2010 until 2018.. Mr. Young served from 1999 until 2009 as Chairman of the board of directors and Chief Executive Officer of Monogram Biosciences, Inc., a biotechnology company. From 1980 to 1999 Mr. Young was employed at Genentech, Inc., most recently as Chief Operating Officer, where he was responsible for all Product Development, Manufacturing and Commercial functions. Prior to joining Genentech, Mr. Young worked at Eli Lilly and Company for 14 years. Mr. Young has been Chairman of NanoString Technologies, a biotechnology company, since 2010 and of Annexon Biosciences, a biotechnology company and Clarus portfolio company, since March 2017. In addition, Mr. Young is a member of the board of directors of Praxis Precision Medicine, a public company, and SFJ Pharmaceuticals, both Clarus portfolio companies. He was a member of the board of directors of Vertex Pharmaceuticals until June 2020 BioMarin, Inc. until October 2015 and Biogen Idec Inc. until June 2014 having served as a director since 1997 and as Chairman of the Board since 2010. Mr. Young is also a Trustee of Montage Health, a nonprofit company. Mr. Young received his M.B.A. from Indiana University and his B.S. in Chemical Engineering from Purdue University, and an honorary Doctorate of Engineering from Purdue University. - William D. Young自2013年10月起担任董事，自2014年4月起担任Theravance Biopharma首席独立董事。在Theravance Biopharma于2014年6月从Innoviva分拆上市之前，Young先生自2001年4月起担任Innoviva的董事。自2018年黑石生命科学收购Claris Ventures以来，他一直担任黑石生命科学的高级顾问。从2010年到2018年，他是Claris Ventures的风险合伙人。Young先生从1999年至2009年担任生物技术公司Monogram Biosciences，Inc.的董事会主席和首席执行官。1980年至1999年，Young先生受雇于基因泰克公司，最近担任首席运营官，负责所有产品开发、制造和商业职能。在加入基因泰克公司之前，Young先生在礼来公司工作了14年。Young先生自2010年起担任生物技术公司NanoString Technologies的董事长，自2017年3月起担任生物技术公司Annexon生物科学公司和Clarus投资组合公司的董事长。此外，Young先生还是上市公司Praxis Precision Medicine和Clarus投资组合公司SFJ Pharmaceuticals的董事会成员。他是Vertex Pharmaceuticals的董事会成员，直到2020年6月，BioMarin，Inc.直到2015年10月，Biogen Idec Inc.直到2014年6月，自1997年起担任董事，自2010年起担任董事会主席。Young先生还是非营利公司Montage Health的受托人。Young先生在印第安纳大学获得工商管理硕士学位，在普渡大学获得化学工程学士学位，并在普渡大学获得荣誉工程学博士学位。
- William D. Young has served as a director since October 2013 and has served as Theravance Biopharma, Inc. lead independent director since April 2014. Prior to Theravance Biopharma, Inc. spin-off from Innoviva in June 2014 and since April 2001 Mr. Young served as a director of Innoviva. He has been a Senior Advisor of Blackstone Life Sciences since 2018 when Blackstone Life Sciences acquired Claris Ventures. He was a Venture Partner at Claris Ventures from 2010 until 2018.. Mr. Young served from 1999 until 2009 as Chairman of the board of directors and Chief Executive Officer of Monogram Biosciences, Inc., a biotechnology company. From 1980 to 1999 Mr. Young was employed at Genentech, Inc., most recently as Chief Operating Officer, where he was responsible for all Product Development, Manufacturing and Commercial functions. Prior to joining Genentech, Mr. Young worked at Eli Lilly and Company for 14 years. Mr. Young has been Chairman of NanoString Technologies, a biotechnology company, since 2010 and of Annexon Biosciences, a biotechnology company and Clarus portfolio company, since March 2017. In addition, Mr. Young is a member of the board of directors of Praxis Precision Medicine, a public company, and SFJ Pharmaceuticals, both Clarus portfolio companies. He was a member of the board of directors of Vertex Pharmaceuticals until June 2020 BioMarin, Inc. until October 2015 and Biogen Idec Inc. until June 2014 having served as a director since 1997 and as Chairman of the Board since 2010. Mr. Young is also a Trustee of Montage Health, a nonprofit company. Mr. Young received his M.B.A. from Indiana University and his B.S. in Chemical Engineering from Purdue University, and an honorary Doctorate of Engineering from Purdue University.
- Muneer A. Satter
-
Muneer A. Satter， 他拥有法学博士学位，工商管理硕士学位。他曾一直任职于我们的董事会（2013年3月以来），以及我们的联席主席兼首席董事。他管理Satter Investment Management公司（SIM，私人投资公司和家庭办公室，拥有几个生命科学和医疗技术公司的巨大投资）。他也曾管理the Satter Foundation（私人家庭基金会）（1997年以来）。他曾一直担任 Akebia Therapeutics公司（上市生物科技公司，专注于贫血和血管疾病的治疗）的主席兼联席主席（2013年5月以来）。2013年10月以来，他曾一直担任Aerpio Therapeutics公司（生物技术公司，专注于糖尿病黄斑水肿和血管渗漏）的联席主席。他是联席创始人，并一直担任Restorsea公司（拥有一个抗衰老面霜独特酶的独家权利）的主席（2013年5月以来）。他曾一直担任Linq3公司（一个独特的彩票交易安全支付平台）的联席主席（2013年5月以来）。他是the Goldman Sachs Foundation和GS Gives公司的董事会副主席，在那里他也担任投资委员会主席，监督12亿美元的资产。他目前任职 the Nature Conservancy 的董事会，在那里他是财政委员会主席，负责监督捐赠16亿美元。他也任职于美国东北大学 （Northeastern University）的监事会。他任职于the American Enterprise Institute的顾问委员会。他是外交关系协会 （The Council on Foreign Relations）成员，并任职于World Business Chicago的董事会（由芝加哥市长Rahm Emanuel主管）。他是高盛投资公司（Goldman Sachs）的退休合伙人，在那里他曾任职公司24年，并担任公司的商业银行业务部门16年的合伙人。他曾担任the Mezzanine Group的全球负责人，在那里他曾筹集和管理超过300亿美元资产。他也曾担任商人银行部门（拥有超过800亿美元的管理资产）的投资委员会高级成员、风险委员会主席。此外，他曾担任Room to Read公司（每年在发展中国家构建2000图书馆和学校）的前任共同主席。他持有美国东北大学 （Northeastern University）的学士学位，以及哈佛法学院（Harvard Law School）和哈佛商学院（Harvard Business School）的法学博士学位和工商管理硕士学位。
Muneer A. Satter has served as a member of our board of directors since December 2014. Mr. Satter has been Founder and Managing Partner of Satter Medical Technology Partners, L.P. since 2016 and Chairman of Satter Investment Management, LLC since 2012 and he also manages the Satter Foundation. Prior to Satter Investment Management, Mr. Satter was a partner at Goldman Sachs where he spent 24 years in various roles, most recently as the Global Head of the Mezzanine Group in the Merchant Banking Division, where he raised and managed over $30 billion of assets and was also Chairman of the Risk Committee overseeing $80 billion of assets. He is the Chairman of the board of directors of Aerpio Pharmaceuticals, a publicly-held biopharmaceutical company. Mr. Satter was Chairman of the board of directors of Akebia Therapeutics, Inc. from May 2013 to December 2018 and was Co-Chairman and a director of Vital Therapies, Inc. from October 2012 to October 2018. He also serves as Vice Chairman of the Goldman Sachs Foundation and GS Gives, is a director of World Business Chicago and Accelerate Institute, is on the Board of Advisors of the American Enterprise Institute, is on the board of directors of the Navy SEAL Foundation, Northwestern Medical Group and is on the Board of Trustees of Northwestern University where he is Chairman of the Finance Committee, as well as on the Board of Trustees of the US Olympic and Paralymic Foundation. Mr. Satter received a B.A. in Economics from Northwestern University, a J.D. from Harvard Law School and an M.B.A. from Harvard Business School. - Muneer A. Satter， 他拥有法学博士学位，工商管理硕士学位。他曾一直任职于我们的董事会（2013年3月以来），以及我们的联席主席兼首席董事。他管理Satter Investment Management公司（SIM，私人投资公司和家庭办公室，拥有几个生命科学和医疗技术公司的巨大投资）。他也曾管理the Satter Foundation（私人家庭基金会）（1997年以来）。他曾一直担任 Akebia Therapeutics公司（上市生物科技公司，专注于贫血和血管疾病的治疗）的主席兼联席主席（2013年5月以来）。2013年10月以来，他曾一直担任Aerpio Therapeutics公司（生物技术公司，专注于糖尿病黄斑水肿和血管渗漏）的联席主席。他是联席创始人，并一直担任Restorsea公司（拥有一个抗衰老面霜独特酶的独家权利）的主席（2013年5月以来）。他曾一直担任Linq3公司（一个独特的彩票交易安全支付平台）的联席主席（2013年5月以来）。他是the Goldman Sachs Foundation和GS Gives公司的董事会副主席，在那里他也担任投资委员会主席，监督12亿美元的资产。他目前任职 the Nature Conservancy 的董事会，在那里他是财政委员会主席，负责监督捐赠16亿美元。他也任职于美国东北大学 （Northeastern University）的监事会。他任职于the American Enterprise Institute的顾问委员会。他是外交关系协会 （The Council on Foreign Relations）成员，并任职于World Business Chicago的董事会（由芝加哥市长Rahm Emanuel主管）。他是高盛投资公司（Goldman Sachs）的退休合伙人，在那里他曾任职公司24年，并担任公司的商业银行业务部门16年的合伙人。他曾担任the Mezzanine Group的全球负责人，在那里他曾筹集和管理超过300亿美元资产。他也曾担任商人银行部门（拥有超过800亿美元的管理资产）的投资委员会高级成员、风险委员会主席。此外，他曾担任Room to Read公司（每年在发展中国家构建2000图书馆和学校）的前任共同主席。他持有美国东北大学 （Northeastern University）的学士学位，以及哈佛法学院（Harvard Law School）和哈佛商学院（Harvard Business School）的法学博士学位和工商管理硕士学位。
- Muneer A. Satter has served as a member of our board of directors since December 2014. Mr. Satter has been Founder and Managing Partner of Satter Medical Technology Partners, L.P. since 2016 and Chairman of Satter Investment Management, LLC since 2012 and he also manages the Satter Foundation. Prior to Satter Investment Management, Mr. Satter was a partner at Goldman Sachs where he spent 24 years in various roles, most recently as the Global Head of the Mezzanine Group in the Merchant Banking Division, where he raised and managed over $30 billion of assets and was also Chairman of the Risk Committee overseeing $80 billion of assets. He is the Chairman of the board of directors of Aerpio Pharmaceuticals, a publicly-held biopharmaceutical company. Mr. Satter was Chairman of the board of directors of Akebia Therapeutics, Inc. from May 2013 to December 2018 and was Co-Chairman and a director of Vital Therapies, Inc. from October 2012 to October 2018. He also serves as Vice Chairman of the Goldman Sachs Foundation and GS Gives, is a director of World Business Chicago and Accelerate Institute, is on the Board of Advisors of the American Enterprise Institute, is on the board of directors of the Navy SEAL Foundation, Northwestern Medical Group and is on the Board of Trustees of Northwestern University where he is Chairman of the Finance Committee, as well as on the Board of Trustees of the US Olympic and Paralymic Foundation. Mr. Satter received a B.A. in Economics from Northwestern University, a J.D. from Harvard Law School and an M.B.A. from Harvard Business School.
- Carol Gallagher
-
Carol Gallagher，自2013年1月起担任董事会成员，自2023年12月起担任董事会首席独立董事。从2014年10月到2023年12月，她担任New Enterprise Associates（一家风险投资公司）的合伙人和风险顾问。加入New Enterprise Associates之前，2013年10月至2014年9月，她担任Frazier Healthcare（一家风险投资公司）的风险合伙人。2008年至2011年，她担任生物制药公司Calistoga Pharmaceuticals的总裁兼首席执行官，当时该公司被Gilead收购。2007年至2008年，她担任Metastatix， Inc.（生物制药公司）的总裁兼首席执行官。在此之前，从1989年开始，她曾在制药公司Eli Lilly and Company、Amgen、Agouron Pharmaceuticals、Pfizer、Biogen Inc.、CancerVax, Inc.和Anadys Pharmaceuticals， Inc.担任各种职务。除了Atara Biotherapeutics， Inc.她于2022年11月加入PMV Pharmaceuticals， Inc.，担任董事。她还在几家私人公司的董事会任职。Gallagher博士此前曾在Mirati Therapeutics（2023年6月至2024年1月，公司被收购）、Turning Point Therapeutics（生物技术公司）（2019年7月至2022年8月，公司被收购）、Frazier Life Sciences Acquisition Corp（特殊目的收购公司）（2020年11月至2022年11月）、Certara Inc.（生物制药工具公司）（2021年6月至2022年4月）、Millendo Therapeutics, Inc.的董事会任职。从2012年9月到2021年6月，她是一家生物技术公司；从2018年10月到2021年2月，她是一家生物制药公司；从2017年11月到2021年4月，她是一家生物制药公司Metacrine， Inc.。她曾就读于Vanderbilt大学，持有Kentucky大学的学士学位和药学博士学位。
Carol Gallagher,has served as a member of the Board since January 2013 and as lead independent Director of the Board since December 2023. From October 2014 to December 2023, Dr. Gallagher served as a partner and then venture advisor with New Enterprise Associates, a venture capital firm. Prior to joining New Enterprise Associates, Dr. Gallagher served as a venture partner with Frazier Healthcare, a venture capital firm, from October 2013 to September 2014. Dr. Gallagher served as the President and Chief Executive Officer of Calistoga Pharmaceuticals, a biopharmaceutical company, from 2008 to 2011, when the company was acquired by Gilead. From 2007 to 2008, Dr. Gallagher was the President and Chief Executive Officer of Metastatix, Inc., a biopharmaceutical company. Prior to that time starting in 1989, she served in various roles at pharmaceutical companies Eli Lilly and Company, Amgen, Agouron Pharmaceuticals, Pfizer, Biogen Inc., CancerVax, Inc. and Anadys Pharmaceuticals, Inc. In addition to Atara Biotherapeutics, Inc. Board, Dr. Gallagher serves as a director at PMV Pharmaceuticals, Inc. which she joined in November 2022. She also serves on several private company boards. Dr. Gallagher previously served on the boards of directors at Mirati Therapeutics from June 2023 until January 2024 when the company was acquired, Turning Point Therapeutics, a biotechnology company, from July 2019 until August 2022 when the company was acquired, Frazier Life Sciences Acquisition Corp., a special purpose acquisition company, from November 2020 until November 2022, Certara Inc., a biopharmaceutical tools company, from June 2021 until April 2022, Millendo Therapeutics, Inc., a biotechnology company, from September 2012 until June 2021, Annexon Biosciences, a biopharmaceutical company, from October 2018 until February 2021, and Metacrine, Inc., a biopharmaceutical company, from November 2017 until April 2021. Dr. Gallagher attended Vanderbilt University and holds B.S. and Doctor of Pharmacy degrees from the University of Kentucky. - Carol Gallagher，自2013年1月起担任董事会成员，自2023年12月起担任董事会首席独立董事。从2014年10月到2023年12月，她担任New Enterprise Associates（一家风险投资公司）的合伙人和风险顾问。加入New Enterprise Associates之前，2013年10月至2014年9月，她担任Frazier Healthcare（一家风险投资公司）的风险合伙人。2008年至2011年，她担任生物制药公司Calistoga Pharmaceuticals的总裁兼首席执行官，当时该公司被Gilead收购。2007年至2008年，她担任Metastatix， Inc.（生物制药公司）的总裁兼首席执行官。在此之前，从1989年开始，她曾在制药公司Eli Lilly and Company、Amgen、Agouron Pharmaceuticals、Pfizer、Biogen Inc.、CancerVax, Inc.和Anadys Pharmaceuticals， Inc.担任各种职务。除了Atara Biotherapeutics， Inc.她于2022年11月加入PMV Pharmaceuticals， Inc.，担任董事。她还在几家私人公司的董事会任职。Gallagher博士此前曾在Mirati Therapeutics（2023年6月至2024年1月，公司被收购）、Turning Point Therapeutics（生物技术公司）（2019年7月至2022年8月，公司被收购）、Frazier Life Sciences Acquisition Corp（特殊目的收购公司）（2020年11月至2022年11月）、Certara Inc.（生物制药工具公司）（2021年6月至2022年4月）、Millendo Therapeutics, Inc.的董事会任职。从2012年9月到2021年6月，她是一家生物技术公司；从2018年10月到2021年2月，她是一家生物制药公司；从2017年11月到2021年4月，她是一家生物制药公司Metacrine， Inc.。她曾就读于Vanderbilt大学，持有Kentucky大学的学士学位和药学博士学位。
- Carol Gallagher,has served as a member of the Board since January 2013 and as lead independent Director of the Board since December 2023. From October 2014 to December 2023, Dr. Gallagher served as a partner and then venture advisor with New Enterprise Associates, a venture capital firm. Prior to joining New Enterprise Associates, Dr. Gallagher served as a venture partner with Frazier Healthcare, a venture capital firm, from October 2013 to September 2014. Dr. Gallagher served as the President and Chief Executive Officer of Calistoga Pharmaceuticals, a biopharmaceutical company, from 2008 to 2011, when the company was acquired by Gilead. From 2007 to 2008, Dr. Gallagher was the President and Chief Executive Officer of Metastatix, Inc., a biopharmaceutical company. Prior to that time starting in 1989, she served in various roles at pharmaceutical companies Eli Lilly and Company, Amgen, Agouron Pharmaceuticals, Pfizer, Biogen Inc., CancerVax, Inc. and Anadys Pharmaceuticals, Inc. In addition to Atara Biotherapeutics, Inc. Board, Dr. Gallagher serves as a director at PMV Pharmaceuticals, Inc. which she joined in November 2022. She also serves on several private company boards. Dr. Gallagher previously served on the boards of directors at Mirati Therapeutics from June 2023 until January 2024 when the company was acquired, Turning Point Therapeutics, a biotechnology company, from July 2019 until August 2022 when the company was acquired, Frazier Life Sciences Acquisition Corp., a special purpose acquisition company, from November 2020 until November 2022, Certara Inc., a biopharmaceutical tools company, from June 2021 until April 2022, Millendo Therapeutics, Inc., a biotechnology company, from September 2012 until June 2021, Annexon Biosciences, a biopharmaceutical company, from October 2018 until February 2021, and Metacrine, Inc., a biopharmaceutical company, from November 2017 until April 2021. Dr. Gallagher attended Vanderbilt University and holds B.S. and Doctor of Pharmacy degrees from the University of Kentucky.
高管简历
中英对照 | 中文 | 英文- Douglas Love
Douglas Love自2014年12月以来一直担任我们的总裁兼首席执行官，并担任我们的董事会成员。加入Annexon公司之前，他曾担任Elan Pharmaceuticals公司（生物制药公司）的运营和战略联盟主管（从2008年到2013年4月），在那里他曾领导Tysabri®；多发性硬化症专营权，以及Elan’；s Alzheimer’；s免疫治疗计划（已获得强生公司公司的许可）。从2006年到2008年，他曾担任Elan公司的战略联盟、业务开发和业务集成主管。在加入Elan之前，Love先生曾担任律师事务所Orrick，Herrington&Sutcliffe LLP的合伙人，Amgen，Inc.的公司法律顾问，以及Genentech，Inc.的部门公司法律顾问，在那里他领导了生物肿瘤学梦百合法律集团。Love先生在南加州大学（University of Southern California）获得工商管理学士学位，并在麦乔治法学院（McGeorge School of Law）以优异成绩获得法学博士学位。
Douglas Love has served as our President and Chief Executive Officer and as a member of our board of directors since December 2014. Prior to joining Annexon, from 2008 to April 2013 he served as Head of Operations & Strategic Alliances for Elan Pharmaceuticals, Inc., a biopharmaceutical company, where he led the Tysabri® multiple sclerosis franchise, and Elan’s Alzheimer’s Immunotherapy Program, which was licensed to Johnson & Johnson. From 2006 to 2008 he served as Head of Strategic Alliances, Business Development & Business Integration for Elan. Prior to joining Elan, Mr. Love served as an associate at the law firm Orrick, Herrington & Sutcliffe LLP, Corporate Counsel at Amgen, Inc. and as Section Corporate Counsel at Genentech, Inc., where he led the BioOncology Healthcare Law Group. Mr. Love received a B.S. in business administration from the University of Southern California and a J.D. with great distinction from McGeorge School of Law.- Douglas Love自2014年12月以来一直担任我们的总裁兼首席执行官，并担任我们的董事会成员。加入Annexon公司之前，他曾担任Elan Pharmaceuticals公司（生物制药公司）的运营和战略联盟主管（从2008年到2013年4月），在那里他曾领导Tysabri®；多发性硬化症专营权，以及Elan’；s Alzheimer’；s免疫治疗计划（已获得强生公司公司的许可）。从2006年到2008年，他曾担任Elan公司的战略联盟、业务开发和业务集成主管。在加入Elan之前，Love先生曾担任律师事务所Orrick，Herrington&Sutcliffe LLP的合伙人，Amgen，Inc.的公司法律顾问，以及Genentech，Inc.的部门公司法律顾问，在那里他领导了生物肿瘤学梦百合法律集团。Love先生在南加州大学（University of Southern California）获得工商管理学士学位，并在麦乔治法学院（McGeorge School of Law）以优异成绩获得法学博士学位。
- Douglas Love has served as our President and Chief Executive Officer and as a member of our board of directors since December 2014. Prior to joining Annexon, from 2008 to April 2013 he served as Head of Operations & Strategic Alliances for Elan Pharmaceuticals, Inc., a biopharmaceutical company, where he led the Tysabri® multiple sclerosis franchise, and Elan’s Alzheimer’s Immunotherapy Program, which was licensed to Johnson & Johnson. From 2006 to 2008 he served as Head of Strategic Alliances, Business Development & Business Integration for Elan. Prior to joining Elan, Mr. Love served as an associate at the law firm Orrick, Herrington & Sutcliffe LLP, Corporate Counsel at Amgen, Inc. and as Section Corporate Counsel at Genentech, Inc., where he led the BioOncology Healthcare Law Group. Mr. Love received a B.S. in business administration from the University of Southern California and a J.D. with great distinction from McGeorge School of Law.
- Sanjay Keswani
Sanjay Keswani自2019年6月起担任我们的执行Vice President兼首席医疗官。在此之前，Keswani博士于2018年9月至2019年6月担任私人生物制药公司Rheos Medicines，Inc.的首席执行官。2015年6月至2018年9月，Keswani博士担任上市制药公司F.Hoffmann-La Roche Ltd.的罗氏制药研究和早期开发部门的高级副总裁兼神经科学，眼科和罕见病全球主管。任职Roche公司之前，他曾担任百时美施贵宝公司公司（上市制药公司）的Vice President、探索性和临床转化研究，在那里他曾负责多种治疗领域，包括免疫学、神经科学、罕见疾病、纤维化和病毒学（2011年3月至2015年6月）。在加入百时美施贵宝之前，Keswani博士曾在上市制药公司礼来公司和上市生物制药公司安进公司担任研究与开发领导职务，并在约翰霍普金斯大学担任神经学助理教授。Keswani博士在伦敦圣巴塞洛缪医院（St.Bartholomew’；s Hospital）获得医学工商管理硕士学位，并在约翰霍普金斯大学医学院（Johns Hopkins University School of Medicine）完成神经病学住院医师学位以及神经免疫学和神经生理学研究金。此外，Keswani博士在伦敦圣玛丽医院（St.Mary’；s Hospital）获得病理与基础医学科学免疫学一级荣誉学位，并当选为皇家内科医师学院院士。
Sanjay Keswani has served as our Executive Vice President and Chief Medical Officer since June 2019. Prior to that, Dr. Keswani was Chief Executive Officer at Rheos Medicines, Inc., a privately-held biopharmaceutical company, from September 2018 to June 2019. From June 2015 to September 2018 Dr. Keswani was Senior Vice President & Global Head of Neuroscience, Ophthalmology and Rare Diseases for the Roche Pharma Research and Early Development division of F. Hoffmann-La Roche Ltd., a publicly-held pharmaceutical company. Prior to Roche, he was Vice President, Exploratory and Clinical Translational Research at Bristol-Myers Squibb Company, a publicly-held pharmaceutical company, where he was responsible for multiple therapeutic areas including Immunology, Neuroscience, Rare Diseases, Fibrosis and Virology from March 2011 to June 2015. Prior to joining Bristol-Myers Squibb, Dr. Keswani held research and development leadership roles at Eli Lilly & Company, a publicly-held pharmaceutical company, and Amgen Inc., a publicly-held biopharmaceutical company, and also served as Assistant Professor in Neurology at Johns Hopkins University. Dr. Keswani received his MBBS in medicine at St. Bartholomew’s Hospital, London and completed his medical residency in Neurology and fellowships in Neuroimmunology and Neurophysiology at Johns Hopkins University School of Medicine. In addition, Dr. Keswani received a first class honors degree from St. Mary’s Hospital, London in Pathology & Basic Medical Sciences Immunology and was elected as a Fellow of the Royal College of Physicians.- Sanjay Keswani自2019年6月起担任我们的执行Vice President兼首席医疗官。在此之前，Keswani博士于2018年9月至2019年6月担任私人生物制药公司Rheos Medicines，Inc.的首席执行官。2015年6月至2018年9月，Keswani博士担任上市制药公司F.Hoffmann-La Roche Ltd.的罗氏制药研究和早期开发部门的高级副总裁兼神经科学，眼科和罕见病全球主管。任职Roche公司之前，他曾担任百时美施贵宝公司公司（上市制药公司）的Vice President、探索性和临床转化研究，在那里他曾负责多种治疗领域，包括免疫学、神经科学、罕见疾病、纤维化和病毒学（2011年3月至2015年6月）。在加入百时美施贵宝之前，Keswani博士曾在上市制药公司礼来公司和上市生物制药公司安进公司担任研究与开发领导职务，并在约翰霍普金斯大学担任神经学助理教授。Keswani博士在伦敦圣巴塞洛缪医院（St.Bartholomew’；s Hospital）获得医学工商管理硕士学位，并在约翰霍普金斯大学医学院（Johns Hopkins University School of Medicine）完成神经病学住院医师学位以及神经免疫学和神经生理学研究金。此外，Keswani博士在伦敦圣玛丽医院（St.Mary’；s Hospital）获得病理与基础医学科学免疫学一级荣誉学位，并当选为皇家内科医师学院院士。
- Sanjay Keswani has served as our Executive Vice President and Chief Medical Officer since June 2019. Prior to that, Dr. Keswani was Chief Executive Officer at Rheos Medicines, Inc., a privately-held biopharmaceutical company, from September 2018 to June 2019. From June 2015 to September 2018 Dr. Keswani was Senior Vice President & Global Head of Neuroscience, Ophthalmology and Rare Diseases for the Roche Pharma Research and Early Development division of F. Hoffmann-La Roche Ltd., a publicly-held pharmaceutical company. Prior to Roche, he was Vice President, Exploratory and Clinical Translational Research at Bristol-Myers Squibb Company, a publicly-held pharmaceutical company, where he was responsible for multiple therapeutic areas including Immunology, Neuroscience, Rare Diseases, Fibrosis and Virology from March 2011 to June 2015. Prior to joining Bristol-Myers Squibb, Dr. Keswani held research and development leadership roles at Eli Lilly & Company, a publicly-held pharmaceutical company, and Amgen Inc., a publicly-held biopharmaceutical company, and also served as Assistant Professor in Neurology at Johns Hopkins University. Dr. Keswani received his MBBS in medicine at St. Bartholomew’s Hospital, London and completed his medical residency in Neurology and fellowships in Neuroimmunology and Neurophysiology at Johns Hopkins University School of Medicine. In addition, Dr. Keswani received a first class honors degree from St. Mary’s Hospital, London in Pathology & Basic Medical Sciences Immunology and was elected as a Fellow of the Royal College of Physicians.
- Michael Overdorf
Michael Overdorf自2020年7月起担任我们的执行Vice President兼首席商务官。在加入Annexon之前，从2001年到2020年7月，Overdorf先生在上市制药公司礼来公司（Eli Lilly&Company）担任过各种执行领导职务，最近，他曾担任公司业务开发和企业战略职务，在那里他曾领导专注于获得创新药物的团队，并领导公司的全球战略的开发和执行。Overdorf先生还担任全球生物制剂平台团队负责人，领导两个针对自身免疫性疾病的生物分子的3期临床开发团队，并担任礼来公司（Lilly）生物药物业务部的首席运营官。Overdorf先生还在礼来公司（Lilly）担任多个商业领导职务，包括英国首席营销官和捷克&斯洛伐克共和国总经理。Overdorf先生是印第安纳大学医学院（Indiana University School of Medicine）临床药理学部门的医学兼职讲师。Mr.Overdorf在Wabash College获得经济学学士学位，在Harvard Business School获得工商管理硕士学位。
Michael Overdorf has served as our Executive Vice President and Chief Business Officer since July 2020. Prior to joining Annexon, from 2001 to July 2020 Mr. Overdorf held various executive leadership roles at Eli Lilly & Company, a publicly-held pharmaceutical company, most recently in Corporate Business Development and Corporate Strategy where he led teams focused on accessing innovative medicines and led the development and execution of the company’s global strategy. Mr. Overdorf also served as a Global Biologics Platform Team Leader, leading two Phase 3 clinical development teams working on biologic molecules targeting autoimmune diseases and as the Chief Operating Officer of the Bio-Medicines Business Unit of Lilly. Mr. Overdorf also held multiple commercial leadership roles at Lilly, including Chief Marketing Officer of the United Kingdom and General Manager of the Czech & Slovak Republics. Mr. Overdorf is an adjunct lecturer in Medicine in the Division of Clinical Pharmacology at the Indiana University School of Medicine. Mr. Overdorf received a B.A. in Economics from Wabash College and an M.B.A. from Harvard Business School.- Michael Overdorf自2020年7月起担任我们的执行Vice President兼首席商务官。在加入Annexon之前，从2001年到2020年7月，Overdorf先生在上市制药公司礼来公司（Eli Lilly&Company）担任过各种执行领导职务，最近，他曾担任公司业务开发和企业战略职务，在那里他曾领导专注于获得创新药物的团队，并领导公司的全球战略的开发和执行。Overdorf先生还担任全球生物制剂平台团队负责人，领导两个针对自身免疫性疾病的生物分子的3期临床开发团队，并担任礼来公司（Lilly）生物药物业务部的首席运营官。Overdorf先生还在礼来公司（Lilly）担任多个商业领导职务，包括英国首席营销官和捷克&斯洛伐克共和国总经理。Overdorf先生是印第安纳大学医学院（Indiana University School of Medicine）临床药理学部门的医学兼职讲师。Mr.Overdorf在Wabash College获得经济学学士学位，在Harvard Business School获得工商管理硕士学位。
- Michael Overdorf has served as our Executive Vice President and Chief Business Officer since July 2020. Prior to joining Annexon, from 2001 to July 2020 Mr. Overdorf held various executive leadership roles at Eli Lilly & Company, a publicly-held pharmaceutical company, most recently in Corporate Business Development and Corporate Strategy where he led teams focused on accessing innovative medicines and led the development and execution of the company’s global strategy. Mr. Overdorf also served as a Global Biologics Platform Team Leader, leading two Phase 3 clinical development teams working on biologic molecules targeting autoimmune diseases and as the Chief Operating Officer of the Bio-Medicines Business Unit of Lilly. Mr. Overdorf also held multiple commercial leadership roles at Lilly, including Chief Marketing Officer of the United Kingdom and General Manager of the Czech & Slovak Republics. Mr. Overdorf is an adjunct lecturer in Medicine in the Division of Clinical Pharmacology at the Indiana University School of Medicine. Mr. Overdorf received a B.A. in Economics from Wabash College and an M.B.A. from Harvard Business School.
- Ted Yednock
Ted Yednock自2013年11月以来一直担任我们的执行Vice President和首席科学官。此前，Yednock博士曾担任Prothena Corporation plc（Elan Pharmaceuticals，Inc.）的首席科学官，该公司是一家从Elan Pharmaceuticals，Inc.分拆出来的上市生物技术公司，直到2013年，1996年至2013年，Yednock博士曾在Elan Pharmaceuticals，Inc.（一家生物制药公司）担任多个职责递增的职位，包括2007年到2013年担任全球研究主管。Yednock从1990年到1996年担任Athena Neurosciences，Inc.（一家私人制药公司）科学家。任职Athena公司期间，他曾担任Tysabri公司（治疗多发性硬化症的单克隆抗体）的科学发明人。除了他在多发性硬化症方面的工作外，Yednock博士还在阿尔茨海默氏症，帕金森氏症，淀粉样变性病，类风湿性关节炎，牛皮癣和克罗恩氏病领域促进了许多药物的发明或进展。Yednock博士在伊利诺伊大学（University of Illinois）获得生物学和化学学士学位，在旧金山加利福尼亚大学（University of California，San Francisco）获得解剖学和细胞生物学博士学位。
Ted Yednock has served as our Executive Vice President and Chief Scientific Officer since November 2013. Previously, Dr. Yednock was Chief Scientific Officer for Prothena Corporation plc, a publicly-held biotechnology company spun out from Elan Pharmaceuticals, Inc., until 2013 and served in several roles of increasing responsibility from 1996 to 2013 at Elan Pharmaceuticals, Inc., a biopharmaceutical company, including Head of Global Research from 2007 to 2013. From 1990 to 1996 Dr. Yednock was a Scientist at Athena Neurosciences, Inc., a privately-held pharmaceutical company. While at Athena, he was the scientific inventor of Tysabri®, a monoclonal antibody for the treatment of multiple sclerosis. In addition to his work in multiple sclerosis, Dr. Yednock has contributed to the invention or progression of numerous drugs in the areas of Alzheimer’s disease, Parkinson’s disease, amyloidosis, rheumatoid arthritis, psoriasis and Crohn’s disease. Dr. Yednock received his B.S. in biology and chemistry from the University of Illinois and his Ph.D. in anatomy and cell biology from the University of California, San Francisco.- Ted Yednock自2013年11月以来一直担任我们的执行Vice President和首席科学官。此前，Yednock博士曾担任Prothena Corporation plc（Elan Pharmaceuticals，Inc.）的首席科学官，该公司是一家从Elan Pharmaceuticals，Inc.分拆出来的上市生物技术公司，直到2013年，1996年至2013年，Yednock博士曾在Elan Pharmaceuticals，Inc.（一家生物制药公司）担任多个职责递增的职位，包括2007年到2013年担任全球研究主管。Yednock从1990年到1996年担任Athena Neurosciences，Inc.（一家私人制药公司）科学家。任职Athena公司期间，他曾担任Tysabri公司（治疗多发性硬化症的单克隆抗体）的科学发明人。除了他在多发性硬化症方面的工作外，Yednock博士还在阿尔茨海默氏症，帕金森氏症，淀粉样变性病，类风湿性关节炎，牛皮癣和克罗恩氏病领域促进了许多药物的发明或进展。Yednock博士在伊利诺伊大学（University of Illinois）获得生物学和化学学士学位，在旧金山加利福尼亚大学（University of California，San Francisco）获得解剖学和细胞生物学博士学位。
- Ted Yednock has served as our Executive Vice President and Chief Scientific Officer since November 2013. Previously, Dr. Yednock was Chief Scientific Officer for Prothena Corporation plc, a publicly-held biotechnology company spun out from Elan Pharmaceuticals, Inc., until 2013 and served in several roles of increasing responsibility from 1996 to 2013 at Elan Pharmaceuticals, Inc., a biopharmaceutical company, including Head of Global Research from 2007 to 2013. From 1990 to 1996 Dr. Yednock was a Scientist at Athena Neurosciences, Inc., a privately-held pharmaceutical company. While at Athena, he was the scientific inventor of Tysabri®, a monoclonal antibody for the treatment of multiple sclerosis. In addition to his work in multiple sclerosis, Dr. Yednock has contributed to the invention or progression of numerous drugs in the areas of Alzheimer’s disease, Parkinson’s disease, amyloidosis, rheumatoid arthritis, psoriasis and Crohn’s disease. Dr. Yednock received his B.S. in biology and chemistry from the University of Illinois and his Ph.D. in anatomy and cell biology from the University of California, San Francisco.
- Jennifer Lew
Jennifer Lew，她于2004年12月加盟Dynavax公司。她在公司担任副总裁，负责金融事务，并担任首席会计师。她曾在Dynavax公司担任高级董事和公司总会计师。在加盟本公司前，她在QRS公司任职。QRS公司是一家上市技术公司。自2002年至2004年，她在QRS公司担任总会计师助理。自2000年至2002年，她担任其董事，负责金融事务。自1994年至1999年，她在Ernst & Young公司任职，其在该公司担任的最后职务是经理。她在克莱蒙特麦肯纳学院（Claremont McKenna College）获得经济学/会计学和Government学士学位。她是一名注册会计师，如今处于非执业状态。
Jennifer Lew,has served as a member of Boundless Bio, Inc. board of directors since January 2022. Ms. Lew has been the EVP and Chief Financial Officer of Annexon Inc., a publicly traded biotechnology company, since June 2019. Prior to Annexon, she served as Chief Financial Officer and previously Senior Vice President, Finance for Aduro Biotech, which merged with Chinook Therapeutics, Inc. (a Novartis company), from 2013 to May 2019. Prior to Aduro, Ms. Lew held various finance roles at Dynavax Technologies Corp., a publicly traded biotechnology company, from 2004 to 2013, and QRS Corporation, a publicly held technology company, from 2000 to 2004. Ms. Lew began her career in the audit practice at Ernst & Young from 1994 to 1999. Ms. Lew received a B.A. in Economics/Accounting and Government from Claremont McKenna College and is a Certified Public Accountant (inactive status). Ms. Lew's background in leadership, finance, and accounting at privately held and publicly traded biotechnology companies contributed to Boundless Bio, Inc. board of directors' conclusion that she should serve as a director of Boundless Bio, Inc.- Jennifer Lew，她于2004年12月加盟Dynavax公司。她在公司担任副总裁，负责金融事务，并担任首席会计师。她曾在Dynavax公司担任高级董事和公司总会计师。在加盟本公司前，她在QRS公司任职。QRS公司是一家上市技术公司。自2002年至2004年，她在QRS公司担任总会计师助理。自2000年至2002年，她担任其董事，负责金融事务。自1994年至1999年，她在Ernst & Young公司任职，其在该公司担任的最后职务是经理。她在克莱蒙特麦肯纳学院（Claremont McKenna College）获得经济学/会计学和Government学士学位。她是一名注册会计师，如今处于非执业状态。
- Jennifer Lew,has served as a member of Boundless Bio, Inc. board of directors since January 2022. Ms. Lew has been the EVP and Chief Financial Officer of Annexon Inc., a publicly traded biotechnology company, since June 2019. Prior to Annexon, she served as Chief Financial Officer and previously Senior Vice President, Finance for Aduro Biotech, which merged with Chinook Therapeutics, Inc. (a Novartis company), from 2013 to May 2019. Prior to Aduro, Ms. Lew held various finance roles at Dynavax Technologies Corp., a publicly traded biotechnology company, from 2004 to 2013, and QRS Corporation, a publicly held technology company, from 2000 to 2004. Ms. Lew began her career in the audit practice at Ernst & Young from 1994 to 1999. Ms. Lew received a B.A. in Economics/Accounting and Government from Claremont McKenna College and is a Certified Public Accountant (inactive status). Ms. Lew's background in leadership, finance, and accounting at privately held and publicly traded biotechnology companies contributed to Boundless Bio, Inc. board of directors' conclusion that she should serve as a director of Boundless Bio, Inc.